[IgA nephropathy: from predicting progression to treatment].
Rauta
Virpi
V
HYKS:n nefrologian klinikka, HUS.
Grönhagen-Riska
Carola
C
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018450:Disease Progression; D005260:Female; D005387:Finland; D005922:Glomerulonephritis, IGA / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D006801:Humans; D007677:Kidney Function Tests; D008297:Male; D011237:Predictive Value of Tests; D011379:Prognosis; D006435:Renal Dialysis / Q000706:statistics & numerical data*; D018570:Risk Assessment; D012720:Severity of Illness Index; D015996:Survival Rate; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors